1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with flunarizine in 1 studies
Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (flunarizine) | Trials (flunarizine) | Recent Studies (post-2010) (flunarizine) |
---|---|---|---|---|---|
9,156 | 187 | 552 | 1,269 | 189 | 153 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akisü, M; Coker, I; Hüseyinov, A; Kültürsay, N | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and flunarizine
Article | Year |
---|---|
Platelet-activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo biloba extract reduce PAF concentration in the brain.
Topics: Animals; Brain; Brain Ischemia; Calcium Channel Blockers; Female; Flunarizine; Ginkgo biloba; Hypoxia, Brain; Male; Plant Extracts; Plants, Medicinal; Platelet Activating Factor; Rats; Rats, Wistar | 1998 |